Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson Read more about Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson
Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting Read more about Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting
Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update Read more about Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals Announces Presentation on CAR-NK Cell Program at SITC 2019 Read more about Bellicum Pharmaceuticals Announces Presentation on CAR-NK Cell Program at SITC 2019
Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update Read more about Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September Read more about Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September
Bellicum Pharmaceuticals Announces Aggregate Gross Proceeds of $69.6 Million from $139.6 Million Public Offering and Private Placement Read more about Bellicum Pharmaceuticals Announces Aggregate Gross Proceeds of $69.6 Million from $139.6 Million Public Offering and Private Placement
Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement Read more about Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement